MUMBAI – A deluge of weight‑loss drugs is set to transform the global fight against obesity as India prepares to unleash low‑cost generic versions of injections like Ozempic after a key patent expired on March 20.

The move will dramatically widen access to treatments that have long been considered a luxury, especially in middle-income countries, where soaring demand has collided with steep prices.